CAS No.70052-12-9,DFMO Suppliers,MSDS download

Products Categories

Pharmaceutical (46)
Others (8)
Organic Chemicals (6)

Basic Information

Molecular Structure:
CAS No.:	70052-12-9
Name:	DFMO
Article Data:	5

Formula:	C₆H₁₂F₂N₂O₂
Molecular Weight:	182.17
Synonyms:	2-(Difluoromethyl)-DL-ornithine;2-(Difluoromethyl)ornithine;DFMO;DFMO (growth regulator);DL-2-(Difluoromethyl)ornithine;DL-a-(Difluoromethyl)ornithine;Elfornithine;Ornidyl;a,d-Diamino-a-(difluoromethyl)valericacid;a-(Difluoromethyl)-DL-ornithine;a-(Difluoromethyl)ornithine;
Density:	1.293g/cm³
Melting Point:	138 °C
Boiling Point:	347 °C at 760 mmHg
Flash Point:	163.7 °C
PSA:	89.34000
LogP:	1.17310

Total:55 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 70052-12-9

Chemistry

IUPAC Name: 2,5-diamino-2-(difluoromethyl)pentanoic acid
Molecular Formula: C₆H₁₂F₂N₂O₂
Molar mass: 182.1685 g/mol
EINECS: 222-760-4
Density: 1.293 g/cm³
Flash Point: 163.7 °C
Index of Refraction: 1.462
Boiling Point: 347 °C at 760 mmHg
Vapour Pressure: 9.72E-06 mmHg at 25°C
Storage temp: Store at 0 °C
Solubility: H₂O >10 mg/mL, soluble
Form: Solid
Color: White
Product categories: facial hair remover
Structure of Eflornithine (CAS NO.70052-12-9):

XLogP3-AA: -2.9
H-Bond Donor: 3
H-Bond Acceptor: 6
IUPAC Name: 2,5-Diamino-2-(difluoromethyl)pentanoic acid
Canonical SMILES: C(CC(C(F)F)(C(=O)O)N)CN
InChI: InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,
12)
InChIKey: VLCYCQAOQCDTCN-UHFFFAOYSA-N

Uses

Eflornithine (CAS NO.70052-12-9) is a drug manufactured by Sanofi-Aventis that has various uses. A recent study (reported 2008 ) conducted by UC Irvine researchers indicates that, when combined with sulindac , Eflornithine significantly reduces the risk of recurring colorectal polyps. It was initially developed for cancer treatment, but, while having little use in treating malignancies. In the United States it is known by the brand name Ornidyl.

Production

Eflornithine (CAS NO.70052-12-9), its production was halted by its manufacturer, Aventis, in 1995 because the company did not consider it a profitable drug. In 2001, after lobbying at the WHO World Health Organization by Médecins Sans Frontières ("Doctors Without Borders"), the manufacturer resumed production of eflornithine, melarsoprol, and pentamidine in sufficient amounts to cover existing needs. As of September 2005, the World Health Organization reports that the India Institute of Chemical Technology in Hyderabad, India and ILEX Oncology in Texas, United States are both working on new ways of making eflornithine more cheaply.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	intravenous	9084mg/kg/2W- (9084mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA	Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987.
man	TDLo	oral	800mg/kg/4D-I (800mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA	Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987.
women	LDLo	intravenous	67mg/kg/40M-C (67mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: PULSE RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	Annals of Internal Medicine. Vol. 105, Pg. 141, 1986.

Safety Profile

Human systemic effects by intravenous route: cardiomyopathy, pulse rate decrease, fall in blood pressure. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of F⁻ and NO_x.

Specification

Eflornithine , its cas register number is 70052-12-9. It also can be called Difluoromethylornithine ; Ornidyl ; Ornithine, 2-(difluoromethyl)- and a-Difluoromethylornithine .